Editorial: Lentiviral vector gene therapy: Effective and safe?

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 861-862

  Persons, Derek A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; BETA GLOBIN; HIGH MOBILITY GROUP A2 PROTEIN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ADRENOLEUKODYSTROPHY; BETA THALASSEMIA; CELL BASED GENE THERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; ENHANCER REGION; GENE EXPRESSION; GENETIC TRANSDUCTION; GENOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LONG TERMINAL REPEAT; MURINE LEUKEMIA VIRUS; NONHUMAN; PATIENT SAFETY; PEER REVIEW; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; METHODOLOGY;

GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS;

EID: 77952001110     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.70     Document Type: Editorial

References (17)

1. Aiuti, A and Roncarolo, MG (2009). Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 682-689.
2. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID) X1 disease. Science 288:669-672. (Pubitemid 30241569)
3. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-2413.
4. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
5. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118:3143-3150.
6. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:198-204.
7. Sorrentino, B (2010). Assessing the risk of lymphomagenesis in gene therapy for SCID-X1: a mouse model shows transformation without vector-induced oncogene activation. Mol Ther 18:868-870.
8. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696.
9. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119:964-975.
10. Felice, B, Cattoglio, C, Cittaro, D, Testa, A, Miccio, A, Ferrari, G et al. (2009). Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One 4: e4571.
11. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823.
12. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117:2225-2232.
13. Schwarzwaelder, K, Howe, SJ, Schmidt, M, Brugman, MH, Deichmann, A, Glimm, H et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117:2241-2249.
14. Kaiser, J. (2009). Gene therapy: beta-thalassemia treatment succeeds, with a caveat. Science 326:1468-1469.
15. Schambach, A, Mueller, D, Galla, M, Verstegen, MM, Wagemaker, G, Loew, R et al. (2006). Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13:1524-1533.
16. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008;16:718-725.
17. Xi, H, Shulha, HP, Lin, JM, Vales, TR, Fu, Y, Bodine, DM et al. (2007). Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. PLoS Genet 3: e136.